BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. It is the first adeno-associated virus (AAV) gene therapy for Hem...
Announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT045...
Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development. On ...
Recommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study 23andMe Holding Co. (Nasdaq: M...
The research was in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine. This study adds to the previous studies of p...
© 2025 Biopharma Boardroom. All Rights Reserved.
